ипилимумаб
Sign in to saveAlso known as MDX-010, MDX-101, MOAB-CTLA-4, MDX-CTLA-4
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2011
- Admin. routes
- parenteral
- Indications
- carcinoma, melanoma, prostate carcinoma, metastatic melanoma
via ChEMBL · EBI
Research
7,201 papers- Improved survival with ipilimumab in patients with metastatic melanoma.The New England journal of medicine · 2010
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.The New England journal of medicine · 2019
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.The New England journal of medicine · 2017
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.The Lancet. Oncology · 2018
- The foundations of immune checkpoint blockade and the ipilimumab approval decennial.Nature reviews. Drug discovery · 2022
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 6 more facts
- route of administration
- intravenous infusion and defusion
- World Health Organisation international non-proprietary name
- ipilimumab
- medical condition treated
- skin cancer
- has characteristic
- biopharmaceutical
- subject has role
- monoclonal antibody
- physically interacts with
- cytotoxic T-lymphocyte associated protein 4
Sources (6)
via Wikidata · CC0
Article · Русский
Ипилимумаб (Ipilimumab или MDX-010 или MDX-101) является лекарственным средством, применяющимся для лечения меланомы, которое в марте 2011 г. было одобрено Управлением по контролю качества пищевых продуктов и лекарственных средств (FDA) США для лечения меланомы поздней стадии под рыночным названием Ервой (Yervoy). Ервой был разработан фармацевтической компанией Bristol Myers Squibb, и представляет собой моноклональное антитело, активизирующее иммунную систему человека. Также Ервой предполагается применять для лечения отдельных форм рака лёгкого и рака простаты.
Abstract from DBpedia / Wikipedia · CC BY-SA